https://www.forex-news.com/
Forex-News has been the world leading economy news website since 2005. It has been a joyful path full of changing variables in this changing world. During the last three years we have also covered some of the most important news regarding Bitcoin and other cryptocurrencies. Wherever the news are, we are there.
, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News
Bitcoin
$42,080.04
-354.96
Ethereum
$2,859.60
-116.44
Litecoin
$151.09
-5.91
DigitalCash
$161.82
-6.4
Monero
$226.64
-0.37
Nxt
$0.02
-0
Ethereum Classic
$47.00
-1.32
Dogecoin
$0.20
-0

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht

9
, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News

[ad_1]

, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021.

The corporate presentation will be available for on-demand viewing beginning September 13, 2021, at 7:00 a.m. ET via the Investors & Media section of Januxs website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

About Janux Therapeutics

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Januxs initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), and its lead TRACIr program targeting PD-L1xCD28, with all of its programs currently in the IND-enabling or discovery stage. For more information, please visit www.januxrx.com.

, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News

[ad_2]

, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News

Get real time updates directly on you device, subscribe now.

, Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference | Nachricht, Forex-News, Forex-News

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More